In-Home Intravenous Dexmedetomidine Infusion for Treatment of Dystonia: A Pediatric Case Report.
Journal
A&A practice
ISSN: 2575-3126
Titre abrégé: A A Pract
Pays: United States
ID NLM: 101714112
Informations de publication
Date de publication:
01 Sep 2024
01 Sep 2024
Historique:
medline:
23
9
2024
pubmed:
23
9
2024
entrez:
23
9
2024
Statut:
epublish
Résumé
The off-label use of an intravenous dexmedetomidine infusion is an option for refractory symptoms in pediatric palliative care with a few published cases of in-home use, most limited to end-of-life care. After an intrathecal baclofen pump malfunction with meningitis and medication withdrawal, a 17-year-old adolescent with quadriparetic cerebral palsy and paroxysmal autonomic instability experienced relief of refractory pain and dystonia with an in-home intravenous dexmedetomidine infusion. His interdisciplinary care team collaborated to establish safety measures and adjust his home medication regimen to further improve quality of life well before his end of life.
Identifiants
pubmed: 39311454
doi: 10.1213/XAA.0000000000001851
pii: 02054229-202409000-00009
doi:
Substances chimiques
Dexmedetomidine
67VB76HONO
Baclofen
H789N3FKE8
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e01851Informations de copyright
Copyright © 2024 International Anesthesia Research Society.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Phan H, Nahata MC. Clinical uses of dexmedetomidine in pediatric patients. Paediatr Drugs. 2008;10:49–69.
Mahmoud M, Barbi E, Mason KP. Dexmedetomidine: what’s new for pediatrics? A narrative review. J Clin Med. 2020;9:2724.
Mason KP, Lerman J. Review article: dexmedetomidine in children: current knowledge and future applications. Anesth Analg. 2011;113:1129–1142.
Burns J, Jackson K, Sheehy KA, Finkel JC, Quezado ZM. The use of dexmedetomidine in pediatric palliative care: a preliminary study. J Palliat Med. 2017;20:779–783.
Cuviello A, Pasli M, Bhatia S, Johnson LM, Anghelescu DL, Baker JN. Dexmedetomidine and propofol at end of life in pediatric oncology: trends in palliative sedation therapy. J Palliat Med. 2023;26:79–86.
De Zen L, Divisic A, Molinaro G, Solidoro S, Barbi E. Dexmedetomidine at home for intractable dystonia and insomnia in children with special needs: a case series. J Pain Symptom Manage. 2023;66:e653–e657.
Bartoletta KM, Collura CA, Thorvilson MJ. Novel use of intranasal dexmedetomidine for refractory irritability in pediatric home care. J Palliat Med. 2023;26:596–598.
Thienprayoon R, Meyer M, Flint H, Weidner N, Hirsch R. Use of continuous dexmedetomidine at home for nearly three years in a young woman with end-stage cyanotic congenital heart disease and cyclic vomiting. J Palliat Med. 2019;22:1289–1292.
Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D; CARE Group. The CARE guidelines: consensus-based clinical case reporting guideline development. BMJ Case Rep. 2013;2013:bcr2013201554.
Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol. 1997;39:214–223.
Campos-Baeta Y, Saavedra-Mitjans M, Garin N, Cardenete J, Cardona D, Riera P. Physicochemical compatibility of dexmedetomidine with parenteral nutrition. Nutr Clin Pract. 2020;35:967–972.
Lemus R, Jacobowski NL, Humphrey L, Tobias JD. Applications of dexmedetomidine in palliative and hospice care. J Pediatr Pharmacol Ther. 2022;27:587–594.
Allen NM, Lin JP, Lynch T, King MD. Status dystonicus: a practice guide. Dev Med Child Neurol. 2014;56:105–112.
Giovannitti JA, Thoms SM, Crawford JJ. Alpha-2 adrenergic receptor agonists: a review of current clinical applications. Anesth Prog. 2015;62:31–39.
Srivastava U, Sarkar ME, Kumar A, et al. Comparison of clonidine and dexmedetomidine for short-term sedation of intensive care unit patients. Indian J Crit Care Med. 2014;18:431–436.